From Bench to Bedside in the Global South: OncoTherad (MRB-CFI-1) Experience as Scalable and Cost-Effective Model for Nanoimmunotherapy Development

This review describes the development and translational application of OncoTherad (MRB‑CFI-1), a novel nanoimmunotherapeutic agent entirely synthesized and validated within a Brazilian public university. Rationally designed through chemical engineering, MRB-CFI-1 is a nanostructured complex formed by the self-assembly of an inorganic phosphate-magnesium scaffold (CFI-1) and a hydrolytic protein (P14-16), resulting in a stable supramolecular complex with strong immunomodulatory activity. Comprehensive physicochemical characterization-including X-ray diffraction, X-ray photoelectron spectroscopy, Fourier-transform infrared spectroscopy (FTIR), dynamic light scattering, zeta potential, and both thermogravimetric and calorimetric analysesconfirmed the crystalline architecture, colloidal stability, and structural integrity of the complex under physiological conditions. These features support the targeted activation of Toll-like receptors 4 and 2, driving robust interferon-mediated immune responses. Preclinical studies demonstrated pronounced antitumor activity, immune remodeling, and safety across bladder, colorectal, and ovarian cancer models. Clinically, OncoTherad achieved a 72.7% complete response rate in patients with non-muscle invasive bladder cancer, extending median recurrence-free survival to 21.4 months without severe adverse events. Under Brazil’s compassionate-use regulation, the formulation was also administered to eight patients with recurrent glioblastoma in combination with second-line chemotherapy, resulting in a median overall survival of 18 months-surpassing historical benchmarks-and radiological stability in 87.5% of cases. A representative patient exhibited a 75% reduction in tumor volume alongside marked neurological recovery. Beyond its therapeutic impact, OncoTherad represents a chemically defined, cost-effective innovation pathway, anchored in sovereign intellectual property and coordinated public-sector efforts. This case highlights the potential of academic nanopharmaceutical development to deliver scalable, high-impact oncologic therapies within emerging health systems.